TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Social well-being improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative incidence of death, myocardial infarction (MI), or target vessel revascularization (TVR)
Endpoint domain: Mortality/survival
Primary endpoint: Need for target vessel revascularization (TVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentrations of CRP and IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of C3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recovery time of intestinal tract function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Promotion of informed choice in maternity care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EPIC Lift Capacity test reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EASI reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core temperature stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma tryptase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy compensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appetite sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global subjective ocular symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: color vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: log10 reduction in serum HCV-RNA levels by week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of radical treatment
Endpoint domain: Mortality/survival
Primary endpoint: T1 90% block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity grade of Post-ERCP Pancreatitis (PEP)
Endpoint domain: Adverse events/effects
Primary endpoint: prevalence of binge drinking reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioequivalence of Clopacin(®) and reference drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to maximal plasma clopidogrel concentration (t max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: terminal elimination half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crohn's disease activity indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: histological scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of back pain
Endpoint domain: Adverse events/effects
Primary endpoint: perception of disaster preparation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perception of general self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in MVIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence based on geometric mean ratios (GMRs) for C(max) and AUC(0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: community functioning improvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: proportion of subjects with less than two visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: in-hospital pulmonary edema
Endpoint domain: Adverse events/effects
Primary endpoint: in-hospital heart failure
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of otorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: itch intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: S.aureus colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: shoulder pain and disability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak load improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in use of walking aids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ARIA‐E
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of cerebral microhemorrhages
Endpoint domain: Adverse events/effects
Primary endpoint: Blood volume and blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable outcome at 1 year
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of vaginal injuries and obstetric trauma in the newborn
Endpoint domain: Adverse events/effects
Primary endpoint: Delay to reperfusion therapy (DtT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: between meal caloric intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pain score from endometrial scratching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reporting quality of RCTs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HPA axis response to stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: bacteria-free specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PWM induced IgM RF synthesis by PBL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: dynamic balance measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral disposition index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving or maintaining PE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AMAT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HS value reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3α‐17 β‐androstenediol glucuronide serum levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving >=3 SCBM per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in PAC-QOL satisfaction score of >=1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in PAC-SYM stool symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma IL-6 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Surrogate markers of bone turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: IBS Symptom Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CES-D measure of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: TIMI major or minor bleeding complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent myocardial infarction (MI) within 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality within 12 months
Endpoint domain: Mortality/survival
Primary endpoint: BPRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SAPS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADRs encountered
Endpoint domain: Adverse events/effects
Primary endpoint: urinary 8-oxo-dG excretion levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased ability to sustain attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: prolonged latencies of visual evoked potential peaks N1 and P2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: reduced amount of fast‐wave activity on the electroencephalogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and tolerability of PUR1900
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma exposure (AUC up to 24 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum concentrations of PUR1900
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TNF‐β levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Morcellation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost analysis (USD per patient)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Satisfaction for pain management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of dreaming
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Thyroid Volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum free-thyroxine index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: fruit shape index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Wall motion index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: visual impairment prevention and treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clarity, glare sensitivity, color perception, and overall vision improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour leakage weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ED admission rate
Endpoint domain: Mortality/survival
Primary endpoint: Plasma pharmacokinetics of intact oxaliplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG motor nerve hyperexcitability scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient-reported acute neurotoxicity symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: mean total percentage misclassified volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of hypokalemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normalization of serum PRL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Tumour volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: average peak force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ultimate load to failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial use of cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly use of cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial use of smokeless tobacco
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly use of smokeless tobacco
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: superficial wound infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: amount of postoperative drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction of PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of PTDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restrictions on high-risk driving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less high-risk driving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum hemagglutination inhibition antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Femoral neck BMD values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of oral MTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality and nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Unstable angina hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Index of Premature Ejaculation (CIPE) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in MVS after 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate (MVS ≤0.5 at t(4w))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving target LDL-C goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Therapeutic alliance with mHealth app
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: complete clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 3-month visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month infiltrate/scar size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: respiratory frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Self-reported dietary intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective measures of dietary intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of IBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adverse effects requiring cessation of therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Severe pancytopenia requiring hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: 24-h mean blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uterine bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentration of placental protein 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Assessment Questionnaire Disability Index (HAQ-DI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CVpef (coefficient of variation of peak expiratory flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Temporal self-similarity (α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing time (days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving more than 50% improvement in physician's global assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Psoriasis Area and Severity Index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epidermal thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean cumulative percentage of 13C dose exhaled after 6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rebound headache incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Urine C‐peptide/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stimulated serum C‐peptide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients exposed to >5 mSv chest radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiological outcomes
Primary endpoint: Median chest radiation exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiological outcomes
Primary endpoint: Median costs for medical care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Endothelial function assessed by reactive hyperemia index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inflammatory state assessed by soluble inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: abstinence from smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of intracoronary mBMC transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: peri-implant tissue health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CFS-OSDI response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: signs/symptoms improvements
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Inhibition of Lp-PLA2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exacerbation symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrathecal pressure (ITP) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mycophenolic acid AUC(0,24 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance on the verbal fluency test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: CFF threshold reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recognition reaction time increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of 'sleep-like' activity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage body weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in risk of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in depression scores in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of PHG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Risk of dying from breast cancer within 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Risk of dying from breast cancer within 20 years
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of CONSORT and CONSORT extension items reported
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in functional ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of the HAQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the MACTAR Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Need for NKP for biliary access
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Urinary day frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Symptoms of urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Vaginal length 3 months postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Duration of total surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reflux resolution rate for ureters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACLS guideline retention score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pass-fail rates for algorithms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition of perineural spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distractor pattern recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes